CTLA4 and non-small cell lung carcinoma: Currently, T‐cell modulating agents are being investigated, where antibodies against CTLA‐4, such as ipilimumab, exhibit great efficacy in treating NSCLC in combination with platinum‐based chemotherapy 37.